In a report released on January 30, David Evans from Kepler Capital maintained a Hold rating on Sanofi (SNYNF – Research Report), with a price ...

Sanofi (SNYNF – Research Report) received a Buy rating and price target from DZ BANK AG analyst Elmar Kraus today. The company’s shares ...

Sanofi’s (NASDAQ:SNY) consumer healthcare unit Opella announced Tuesday that the U.S. FDA has lifted a clinical hold on a ...

After hitting a regulatory roadblock in 2022, Sanofi’s consumer healthcare business Opella has secured the FDA’s blessing to ...

Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...

Tamiflu was a blockbuster product for Roche over a ... Tamiflu has been approved in New Zealand as an OTC drug since 2007, and that will likely assist Sanofi as it tries to persuade the FDA ...

Looking ahead, Sanofi has announced an ambitious share buyback program worth 5 billion euros for 2025, signaling strong confidence in its future prospects. The company projects mid to high ...

The three pipelines-in-a-product are anti-OX40 ... through 2030 and beyond.” Sanofi's consumer healthcare unit Opella could finally be able to bring an OTC PDE-5 inhibitor for erectile ...

French pharma major Sanofi’s consumer healthcare business, Opella, has announced that the US Food and Drug Administration ...

(RTTNews) - Sanofi's Consumer Healthcare division ... from a prescription-only medication to an over-the-counter option. With this decision, the actual use trial can now proceed, marking Cialis ...